ID   Hs 766T
AC   CVCL_0334
SY   Hs 766.T; HS-766T; Hs-766T; HS 766T; HS-766-T; Hs-766-T; HS766T; Hs766T; H766T; 766T; Hs 766
DR   BTO; BTO:0003267
DR   CLO; CLO_0004102
DR   EFO; EFO_0006590
DR   MCCL; MCC:0000230
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-134
DR   BioGRID_ORCS_Cell_line; 417
DR   BioSample; SAMN03471934
DR   BioSample; SAMN03472713
DR   BioSample; SAMN10988214
DR   cancercelllines; CVCL_0334
DR   CCRID; 1101HUM-PUMC000377
DR   Cell_Model_Passport; SIDM00664
DR   CGH-DB; 166-1
DR   CGH-DB; 9276-4
DR   ChEMBL-Cells; CHEMBL3308000
DR   ChEMBL-Targets; CHEMBL612597
DR   Cosmic; 868240
DR   Cosmic; 873005
DR   Cosmic; 913311
DR   Cosmic; 922254
DR   Cosmic; 932519
DR   Cosmic; 923169
DR   Cosmic; 947401
DR   Cosmic; 948380
DR   Cosmic; 948738
DR   Cosmic; 949323
DR   Cosmic; 1006370
DR   Cosmic; 1108344
DR   Cosmic; 1122344
DR   Cosmic; 1299301
DR   Cosmic; 1320468
DR   Cosmic; 1366279
DR   Cosmic; 1518235
DR   Cosmic; 1571778
DR   Cosmic; 2434086
DR   Cosmic; 2755952
DR   Cosmic-CLP; 1298141
DR   DepMap; ACH-000178
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1298141
DR   GEO; GSM206513
DR   GEO; GSM621912
DR   GEO; GSM784692
DR   GEO; GSM887117
DR   GEO; GSM888188
DR   GEO; GSM1024403
DR   GEO; GSM1374553
DR   GEO; GSM1374554
DR   GEO; GSM1374555
DR   GEO; GSM1669899
DR   IARC_TP53; 21071
DR   IARC_TP53; 315
DR   LiGeA; CCLE_905
DR   LINCS_LDP; LCL-1737
DR   PharmacoDB; Hs766T_596_2019
DR   PRIDE; PXD003198
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0334
DR   PubChem_Cell_line; CVCL_0334
DR   SKY/M-FISH/CGH; 1994
DR   Wikidata; Q54896006
RX   DOI=10.4172/jpb.1000057;
RX   PubMed=176412;
RX   PubMed=283258;
RX   PubMed=761205;
RX   PubMed=1630814;
RX   PubMed=6500159;
RX   PubMed=8026879;
RX   PubMed=10027410;
RX   PubMed=10408907;
RX   PubMed=11169959;
RX   PubMed=14695172;
RX   PubMed=15126341;
RX   PubMed=15367885;
RX   PubMed=15688027;
RX   PubMed=16912165;
RX   PubMed=18380791;
RX   PubMed=20418756;
RX   PubMed=22460905;
RX   PubMed=22585861;
RX   PubMed=25167228;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26216984;
RX   PubMed=26589293;
RX   PubMed=27259358;
RX   PubMed=27397505;
RX   PubMed=29444439;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   https://www.cellosaurus.org/pawefish/PancCellLineDescriptions/Hs766T.html
WW   http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=Hs%20766T
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 6-7 days (PubMed=176412); 30 hours (PubMed=25984343).
CC   HLA typing: A*03:01,26:01; B*35:01,38:01; C*04:01,12:03 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=10408907; PubMed=15367885; PubMed=18380791).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Homozygous (PubMed=11169959; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8026879; PubMed=15367885).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Metabolome analysis.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.11%; Native American=0.92%; East Asian, North=1.96%; East Asian, South=0%; South Asian=1.54%; European, North=62.85%; European, South=32.62% (PubMed=30894373).
CC   Caution: Indicated as originating from a 46 year old male patient in ATCC and from a 64 year old male patient in PubMed=283258 and PubMed=761205.
CC   Caution: Incorrectly reported to have no KRAS mutation in PubMed=8026879 and PubMed=15367885.
CC   Caution: TP53 mutation indicated incorrectly as being at c.542G>A in PubMed=1630814.
CC   Misspelling: Hs-776-T; Cosmic=873005; Cosmic=948380; PubMed=10408907.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): ATCC; CCRID; Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,11
ST   D16S539: 9,11,12 (PubMed=25877200)
ST   D16S539: 9,12 (ATCC; CCRID; Cosmic-CLP)
ST   D18S51: 13
ST   D19S433: 15
ST   D21S11: 28
ST   D2S1338: 18,26
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 10
ST   D8S1179: 12,14
ST   FGA: 19,20
ST   Penta D: 9
ST   Penta E: 7,12
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C8294; Pancreatic adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   DOI=10.4172/jpb.1000057;
RA   Yamada M., Fujii K., Koyama K., Hirohashi S., Kondo T.;
RT   "The proteomic profile of pancreatic cancer cell lines corresponding
RT   to carcinogenesis and metastasis.";
RL   J. Proteomics Bioinformatics 2:1-18(2009).
//
RX   PubMed=176412; DOI=10.1093/jnci/56.4.843;
RA   Owens R.B., Smith H.S., Nelson-Rees W.A., Springer E.L.;
RT   "Epithelial cell cultures from normal and cancerous human tissues.";
RL   J. Natl. Cancer Inst. 56:843-849(1976).
//
RX   PubMed=283258; DOI=10.1093/jnci/62.2.225;
RA   Smith H.S.;
RT   "In vitro properties of epithelial cell lines established from human
RT   carcinomas and nonmalignant tissue.";
RL   J. Natl. Cancer Inst. 62:225-230(1979).
//
RX   PubMed=761205;
RA   Smith H.S., Springer E.L., Hackett A.J.;
RT   "Nuclear ultrastructure of epithelial cell lines derived from human
RT   carcinomas and nonmalignant tissues.";
RL   Cancer Res. 39:332-344(1979).
//
RX   PubMed=1630814;
RA   Ruggeri B., Zhang S.-Y., Caamano J., DiRado M., Flynn S.D.,
RA   Klein-Szanto A.J.P.;
RT   "Human pancreatic carcinomas and cell lines reveal frequent and
RT   multiple alterations in the p53 and Rb-1 tumor-suppressor genes.";
RL   Oncogene 7:1503-1511(1992).
//
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
//
RX   PubMed=8026879; DOI=10.1002/ijc.2910580207;
RA   Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.;
RT   "Comparative analysis of mutations in the p53 and K-ras genes in
RT   pancreatic cancer.";
RL   Int. J. Cancer 58:185-191(1994).
//
RX   PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4;
RA   Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A.,
RA   Meltzer P.S., Ried T.;
RT   "Specific chromosomal aberrations and amplification of the AIB1
RT   nuclear receptor coactivator gene in pancreatic carcinomas.";
RL   Am. J. Pathol. 154:525-536(1999).
//
RX   PubMed=10408907; DOI=10.1016/S0304-3835(98)00380-2;
RA   Bartsch D.K., Barth P., Bastian D., Ramaswamy A., Gerdes B.,
RA   Chaloupka B., Deiss Y., Simon B., Schudy A.;
RT   "Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell
RT   lines than in primary pancreatic adenocarcinomas.";
RL   Cancer Lett. 139:43-49(1999).
//
RX   PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C;
RA   Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M.,
RA   Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.;
RT   "Non-random chromosomal rearrangements in pancreatic cancer cell lines
RT   identified by spectral karyotyping.";
RL   Int. J. Cancer 91:350-358(2001).
//
RX   PubMed=14695172;
RA   Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V.,
RA   Shen-Ong G.L., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J.,
RA   Kern S.E., Goggins M.G., Hruban R.H.;
RT   "Highly expressed genes in pancreatic ductal adenocarcinomas: a
RT   comprehensive characterization and comparison of the transcription
RT   profiles obtained from three major technologies.";
RL   Cancer Res. 63:8614-8622(2003).
//
RX   PubMed=15126341; DOI=10.1158/0008-5472.CAN-03-3159;
RA   Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L.,
RA   Veltman J.A., van Kessel A.G., Hoglund M.;
RT   "Genome-wide array-based comparative genomic hybridization reveals
RT   multiple amplification targets and novel homozygous deletions in
RT   pancreatic carcinoma cell lines.";
RL   Cancer Res. 64:3052-3059(2004).
//
RX   PubMed=15367885; DOI=10.1097/00006676-200410000-00004;
RA   Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M.,
RA   Hirohashi S.;
RT   "Orthotopic transplantation models of pancreatic adenocarcinoma
RT   derived from cell lines and primary tumors and displaying varying
RT   metastatic activity.";
RL   Pancreas 29:193-203(2004).
//
RX   PubMed=15688027; DOI=10.1038/sj.onc.1208383;
RA   Heidenblad M., Lindgren D., Veltman J.A., Jonson T., Mahlamaki E.H.,
RA   Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.;
RT   "Microarray analyses reveal strong influence of DNA copy number
RT   alterations on the transcriptional patterns in pancreatic cancer:
RT   implications for the interpretation of genomic amplifications.";
RL   Oncogene 24:1794-1801(2005).
//
RX   PubMed=16912165; DOI=10.1158/0008-5472.CAN-06-0721;
RA   Calhoun E.S., Hucl T., Gallmeier E., West K.M., Arking D.E.,
RA   Maitra A., Iacobuzio-Donahue C.A., Chakravarti A., Hruban R.H.,
RA   Kern S.E.;
RT   "Identifying allelic loss and homozygous deletions in pancreatic
RT   cancer without matched normals using high-density single-nucleotide
RT   polymorphism arrays.";
RL   Cancer Res. 66:7920-7928(2006).
//
RX   PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x;
RA   Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A.,
RA   Shiratori K., Hirohashi S., Inazawa J., Imoto I.;
RT   "Identification of SMURF1 as a possible target for 7q21.3-22.1
RT   amplification detected in a pancreatic cancer cell line by in-house
RT   array-based comparative genomic hybridization.";
RL   Cancer Sci. 99:986-994(2008).
//
RX   PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963;
RA   Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J.,
RA   Scaife C.L., Firpo M.A., Mulvihill S.J.;
RT   "Phenotype and genotype of pancreatic cancer cell lines.";
RL   Pancreas 39:425-435(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=25167228; DOI=10.1038/bjc.2014.475;
RA   Hamidi H., Lu M., Chau K., Anderson L., Fejzo M.S., Ginther C.,
RA   Linnartz R., Zubel A., Slamon D.J., Finn R.S.;
RT   "KRAS mutational subtype and copy number predict in vitro response of
RT   human pancreatic cancer cell lines to MEK inhibition.";
RL   Br. J. Cancer 111:1788-1801(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26216984; DOI=10.1073/pnas.1501605112;
RA   Daemen A., Peterson D., Sahu N., McCord R., Du X.-N., Liu B.,
RA   Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R.,
RA   Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.L.,
RA   Manning G., Settleman J., Hatzivassiliou G., Evangelista M.;
RT   "Metabolite profiling stratifies pancreatic ductal adenocarcinomas
RT   into subtypes with distinct sensitivities to metabolic inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27259358; DOI=10.1074/mcp.M116.058313;
RA   Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M.,
RA   Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K.,
RA   Biankin A.V., Wu J.-M., Daly R.J.;
RT   "Resolution of novel pancreatic ductal adenocarcinoma subtypes by
RT   global phosphotyrosine profiling.";
RL   Mol. Cell. Proteomics 15:2671-2685(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//